Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Healthcare Biotechnology

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

Bullboard Posts

Post by Riverfolkon May 15, 2020 10:41am

128 Views

Post# 31033095

Covid19 - Treatment - 83% Survival Rate

I have received a lot of interest from my post last night. The information I posted was from the world renowned scientist publication at CELL. Please see link below:

"Results found that an increase in overall survival from 0 to 57% when the first dose of Metablok was administered; at hour 18, mice given a second dose of Metablok saw in an increase in survival from 57% to 83%."

This science, coupled with the fact that Metablok treatment reduces inflammation in the LUNG, KIDNEY and LIVER while hospitals are now claiming 36.6% of Covid patients are suffering from kidney failure, make Arch Biopartners very attractive at 77.8million market cap.

https://www.cell.com/action/showPdf?pii=S0092-8674%2819%2930782-2

FYI - this publication is expensive on the CPU, download the app and buy it for $5.99, it may be the smartest decision to get ahead of the market IMHO